Novo Nordisk aims higher than analysts in 2022 outlook

Nevertheless, 2022 won’t go as well for Novo Nordisk as 2021, the company says.

Photo: Novo Nordisk Pharmatech/PR

In Novo Nordisk’s full-year financial report, which was released on Wednesday morning, the Danish pharmaceutical giant predicts less growth in 2022 than what it just booked in 2021. The company also estimates that its 2022 sales growth will land in the 6–10 percent range in constant exchange rates (CER) compared to 14 percent in 2021, while the operating profit growth will be between 4–8 percent at CER against the reported 13 percent in 2021.

Prior to the report, analysts had predicted top line growth of 7.8 percent at CER and operating growth of 5.4 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs